The efficacy of the pancreatic enzyme replacement on small intestinal bacterial overgrowth in patients with pancreatectomy: A prospective, single-arm clinical trial

The Catholic University of Korea, St. Vincent's Hospital0 个研究点目标入组 69 人开始时间: 待定最近更新: 2021年6月24日

适应症

试验速览

暂无简介。

•Patients who underwent pancreatic resection for pancreatic lesions and were diagnosed with a cure for at least 6 months by pathology and were accompanied by one or more of the following symptoms of the digestive system: abdominal pain, abdominal discomfort, abdominal distension, diarrhea, fatty stool, nausea, and vomiting.

•A. Those who received antibiotics within 3 months
•B. Patients currently undergoing chemotherapy
•C. Patients with tumor recurrence, stenosis, or organic obstruction by gastrointestinal endoscopy or gastrointestinal angiography
•D. Patients who had gastrointestinal surgery (except appendectomy and gallbladder surgery)
•E. Have a digestive disorder (e.g., gastric ulcer, duodenal ulcer, esophageal cancer, gastric cancer, small enteritis, colitis, etc.) that may affect the exercise evaluation of the digestive system within the last 15 days
•F. Those with diseases that have a significant impact on this study (E.g., renal failure of 3.0 mg/dL or more of creatinine in the blood, liver disease corresponding to Child-Pugh classification C)
•G. In the case of taking drugs, such as narcotic drugs, probiotics, laxatives, etc., that may affect the exercise evaluation of the digestive system (except for those who have a drug holiday of 7 days or more)
•H. Pregnant/nursing women (when registering women of childbearing age, check pregnancy test)
•I. When communication is difficult due to hearing impairment
•J. Patients currently participating in other research trials
•K. Others, the person in charge of the research test or the person in charge determines that it is inappropriate

发起方